Across diabetes, obesity, hypertension, chronic kidney disease and lipid management, a clear message emerged at CMHC 2026: treatment innovation is accelerating at an extraordinary pace. The science is becoming increasingly sophisticated, with new therapies, diagnostics and technologies reshaping what is possible. Yet throughout the conference, one theme repeatedly surfaced: our ability to generate evidence is advancing faster than our ability to help people act on it. The most important questions are no longer simply can we treat disease? They are who should be treated, when should intervention begin, and how can we support sustained engagement over time? From Siloed Care to Connected Care One of the strongest themes of the conference was the move toward a more integrated cardiometabolic model. The overlap between cardiovascular disease, diabetes, obesity and kidney disease is now impossible to ignore. New clinical guidance, including the recently released cardio-kidney-metabolic recommendations, reflects a growing emphasis on patient-centred, multidisciplinary care. As one speaker succinctly put it: “We treat all the things.” For healthcare professionals, researchers and brands alike, this signals a shift away from isolated treatment approaches and toward a more holistic view of patient health. Expanding Possibilities, Increasing Complexity The expanding role of GLP-1 and incretin therapies illustrated this shift perfectly. Once discussed primarily in relation to weight management and glucose control, these therapies are now associated with cardiovascular outcomes, CKD and MASH, while investigations continue across conditions including Alzheimer’s disease, Parkinson’s disease, osteoarthritis, HFpEF and PCOS. As therapies increasingly influence multiple organ systems, important questions emerge around ownership, treatment pathways and outcome measurement. Success becomes harder to define when a single intervention may deliver benefits across several disease areas simultaneously. A similar theme emerged in discussions around prevention. Sessions exploring dementia highlighted growing evidence linking mid-life vascular risk factors with cognitive health later in life, reinforcing the connection between cardiovascular and brain health. This broadening of cardiometabolic medicine brings new audiences, new stakeholder groups and new motivations for behaviour change. It also increases the need for clear, evidence-based communication that distinguishes between established benefits, emerging evidence and future potential. Can Cardiology Learn from Oncology? One of the most thought-provoking discussions came from the atherosclerosis sessions, where speakers argued that cardiovascular approaches should adopt lessons from oncology. The premise was simple: oncologists use imaging to identify disease, stage progression, personalise treatment and monitor response. Cardiovascular care may increasingly move in the same direction. Advances in AI-assisted coronary CT imaging now allow clinicians to quantify plaque burden and characterise plaque phenotype. This means we can increasingly see not just how much coronary plaque someone has, but what sort of plaque it is and whether it has characteristics associated with higher risk. This can make disease staging and monitoring more feasible than ever before. This thinking aligns with a broader conference message: We don’t treat what we don’t measure. Across discussions on Lp(a), inflammation and lifetime LDL-C exposure, there was a growing consensus that earlier measurement, earlier intervention and more personalised prevention strategies will play an increasingly important role in future care. Yet this approach also raises an important behavioural question. How will people respond to being told they have evidence of disease before experiencing symptoms? As prevention becomes more imaging-led, communication and patient support will become just as important as the technology itself. Turning Information into Action Perhaps the most consistent challenge discussed throughout CMHC was implementation. Despite advances in treatments, diagnostics and digital health technologies, behaviour remains the critical factor that determines outcomes. Research presented at the conference reinforced that structured support often produces better results than education alone. However, many interventions struggle to maintain their impact once support is removed. Similarly, while GLP-1 therapies can deliver meaningful weight loss, speakers noted that improvements in diet quality, physical activity and long-term adherence do not automatically follow – turning to treatments as an alternative to a healthier lifestyle. The same challenge extends to technology. From continuous glucose monitoring to AI-enabled diagnostics, innovation is producing more data than ever before. However, understanding, trust and action often lag behind. Education, context and behavioural support will be essential if these tools are to realise their full potential. Without them, there is a risk of increasing confusion rather than empowering better decision-making. What This Means for Brands For organisations operating in the cardiometabolic space, the future presents both opportunity and complexity. There are more therapies, more indications, more data sources and more stakeholders than ever before. The challenge is ensuring these advances translate into meaningful action rather than noise. The most effective strategies will focus on helping healthcare professionals and patients navigate complexity through clear, relevant and actionable communication. Ultimately, the gap that matters is not between innovation and evidence. It is the gap between: -Belief – excitement about a new therapy, technology or approach -Intention – willingness to adopt it -Behaviour – sustained prescribing, adherence and lifestyle change Closing that gap requires a deeper understanding of how people make decisions, how trust is built and maintained, and how environments can support healthy behaviour over time. If cardiology is to become “more oncology”, it may need to borrow not only oncology’s clinical practices, but also its understanding of how to communicate risk, support patients through diagnosis and maintain engagement throughout the care journey. As CMHC 2026 demonstrated, the future of cardiometabolic health will be defined not only by better treatments, but by our ability to help people act on them. To find out more about this year’s event, speak to HRW Cardiometabolic by filling in the Contact for below. By Esme Barrow-Williams and Hilla Israeli Apply Now!